Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening  Iris Lansdorp-Vogelaar,

Similar presentations


Presentation on theme: "Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening  Iris Lansdorp-Vogelaar,"— Presentation transcript:

1 Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening  Iris Lansdorp-Vogelaar, S. Lucas Goede, Linda J.W. Bosch, Veerle Melotte, Beatriz Carvalho, Manon van Engeland, Gerrit A. Meijer, Harry J. de Koning, Marjolein van Ballegooijen  Clinical Gastroenterology and Hepatology  Volume 16, Issue 4, Pages e11 (April 2018) DOI: /j.cgh Copyright © 2018 AGA Institute Terms and Conditions

2 Figure 1 Net costs and LYG (3% discounted) of efficient FIT screening strategies and of screening strategies with a hypothetical biomarker with 90% sensitivity for cancer, 48% for advanced adenomas, and 88% specificity. Biomarker tests costs are equal to €50 ($56) in (A), to €15 ($17) in (B), and €25 ($28) in (C). Each symbol represents a strategy that differs with respect to age to begin screening, age to end screening, and screening interval. Clinical Gastroenterology and Hepatology  , e11DOI: ( /j.cgh ) Copyright © 2018 AGA Institute Terms and Conditions

3 Supplementary Figure 1 Structure of MISCAN-Colon model.
Clinical Gastroenterology and Hepatology  , e11DOI: ( /j.cgh ) Copyright © 2018 AGA Institute Terms and Conditions

4 Supplementary Figure 2 Adenoma and cancer stages in MISCAN-Colon model. Cancer stages correspond to the American Joint Committee on Cancer/International Union Against Cancer staging system for CRC. Adenomas are categorized by size. The size-specific prevalence of adenomas as well as the proportion of adenomas that ever develop into cancer are dependent on age. Clinical Gastroenterology and Hepatology  , e11DOI: ( /j.cgh ) Copyright © 2018 AGA Institute Terms and Conditions

5 Supplementary Figure 3 Modelling natural history into life history.
Clinical Gastroenterology and Hepatology  , e11DOI: ( /j.cgh ) Copyright © 2018 AGA Institute Terms and Conditions

6 Supplementary Figure 4 Modelling screening into life history.
Clinical Gastroenterology and Hepatology  , e11DOI: ( /j.cgh ) Copyright © 2018 AGA Institute Terms and Conditions


Download ppt "Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening  Iris Lansdorp-Vogelaar,"

Similar presentations


Ads by Google